

=> d his

(FILE 'HOME' ENTERED AT 18:28:32 ON 13 JUN 2004)

FILE 'MEDLINE, BIOSIS' ENTERED AT 18:28:48 ON 13 JUN 2004

L1 0 S PRO7170
L2 3446 S GLUCOSE (L) FATTY ACID? (L) UPTAKE
L3 17962 S (GLUCOSE OR FATTY ACID?) (W) UPTAKE
L4 468 S GLUCOSE (L) FATTY ACID? (L) UPTAKE (L) SKELETAL MUSCLE
L5 277 DUP REM L4 (191 DUPLICATES REMOVED)
L6 238 S L5 AND PY<2003
L7 386 S (ASHKENAZI, A?)/AU
L8 0 S L6 AND L7
L9 0 S EXMAD

L Number	Hits	Search Text	DB	Time stamp
-	134	PRO7170	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:16
-	755	bandman-o\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:53
-	4	EXMAD	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:21
-	3001	glucose adj uptake	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:22
-	391	glucose with fatty adj acid with uptake	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:23
-	4469	(glucose fatty adj acid) with uptake	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:22
-	3039	((glucose fat\$ adj acid\$) with uptake) and (fus\$ chimeric Ig flag)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:24
-	3	EXMAD and (fus\$ chimeric Ig flag)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:25
-	3	EXMAD and (fus\$ chimeric immunoglobulin flag heterol\$ tag his)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:26
-	649	ashkenazi-a\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:49
-	133	PRO7170 and ashkenazi-a\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:49
-	27	(glucose with fatty adj acid with uptake) and ashkenazi-a\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:53
-	134	PRO7170 and antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:53
-	4	EXMAD and antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/06/08 17:53

XX PRO polynucleotides used to produce polypeptides used to target
 PT bioactive molecules such as toxins, radiolabels or antibodies, to
 PT specific cells, to cause targeted cell death -
 XX
 PS Claim 12; Fig 326; 935pp; English.
 XX
 CC The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridisation probes, in
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.
 XX
 PS Sequence 482 AA;

Query Match 100.0%; Score 2429; DB 22; Length 482;
 Best Local Similarity 100.0%; Pred. No. 1e-148;
 Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGCLWGLALPLFFCWEVGVSGSAGSTRADTAMTDDTEVPMTLAPGHALETQTL 60
 Db 1 MGCLWGLALPLFFCWEVGVSGSAGSTRADTAMTDDTEVPMTLAPGHALETQTL 60
 QY 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFWLIATSVETSAAGSPE 120
 Db 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFWLIATSVETSAAGSPE 120
 QY 121 GAGMTTQTITGSDPEBAIFDTLCTDDSSBEAKLTMDILTLAHTSTEAKGLSESSASS 180
 Db 121 GAGMTTQTITGSDPEBAIFDTLCTDDSSBEAKLTMDILTLAHTSTEAKGLSESSASS 180
 QY 181 DGHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASS 240
 Db 181 DGHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASS 240
 QY 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
 Db 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
 QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLGALVTVSRNPLE 360
 Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLGALVTVSRNPLE 360
 QY 361 ETSALSVEITPSYKVGSAAPVSIAGSAVGKTTSFAGSSASSYSPGEALKNFTPSETPT 420
 Db 361 ETSALSVEITPSYKVGSAAPVSIAGSAVGKTTSFAGSSASSYSPGEALKNFTPSETPT 420
 QY 421 MDIATKGPPTSDRDLPSVPTTNSRGNTSLAKITTSKATMTKPPQPRPLPCGRP 480
 Db 421 MDIATKGPPTSDRDLPSVPTTNSRGNTSLAKITTSKATMTKPPQPRPLPCGRP 480
 QY 481 QT 482
 Db 481 QT 482

RESULT 4
 AAB27225
 ID AAB27225 standard; Protein; 482 AA.

XX AC AAB27225;

XX AC 27-MAR-2001 (first entry)

XX

DE Human EXMAD-3 SEQ ID NO: 3.
 XX
 KW Extracellular matrix and adhesion-associated protein; EXMAD; cancer;
 KW inflammation; reproductive disorder; cardiovascular disorder;
 KW immune disorder; musculoskeletal disorder; developmental disorder;
 KW gastrointestinal disorder; cell proliferation disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200068380-A2.
 XX
 PD 16-NOV-2000.
 XX
 PF 10-MAY-2000; 2000WO-US12811.
 XX
 PR 11-MAY-1999; 99US-0133643.
 PR 23-AUG-1999; 99US-0150409.
 XX
 PA (INCY-) INCYTE GENOMICS INC.
 XX
 PI Bandman O, Hillman JL, Tang YT, Lal P, Yue H, Baughn MR, Lu DAM;
 PI Azimzai Y;
 XX
 DR WPI; 2001-007395/01.
 DR N-PSDB; AAC66892.
 XX
 PT Isolated polynucleotide encoding extracellular matrix or
 PT adhesion-associated protein (EXMAD) useful for diagnosing, treating, or
 PT preventing disorders associated with expression of EXMAD such as
 PT proliferative, immune and genetic disorders -
 XX
 PS Claim 1; Page 89-90; 129pp; English.
 XX
 CC The present invention provides the protein and coding sequences for 25
 CC novel extracellular matrix and adhesion-associated proteins (EXMADs).
 CC These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,
 CC EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,
 CC EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,
 CC EXMAD-20, EXMAD-21, EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are
 CC useful in the prevention and treatment of cancers, cell proliferation,
 CC cardiovascular, reproductive, immune, musculoskeletal, developmental and
 CC gastrointestinal disorders and inflammation.
 XX
 PS Sequence 482 AA;
 QY Query Match 100.0%; Score 2429; DB 22; Length 482;
 Db Best Local Similarity 100.0%; Pred. No. 1e-148;
 QY Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 MGCLWGLALPLFFCWEVGVSGSAGSTRADTAMTDDTEVPMTLAPGHALETQTL 60
 QY 1 MGCLWGLALPLFFCWEVGVSGSAGSTRADTAMTDDTEVPMTLAPGHALETQTL 60
 Db 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFWLIATSVETSAAGSPE 120
 QY 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFWLIATSVETSAAGSPE 120
 Db 61 SAETSSRASTPAGPIPEAETRGAKRISPAETRSFTKTSNFWLIATSVETSAAGSPE 120
 QY 121 GAGMTTQTITGSDPEBAIFDTLCTDDSSBEAKLTMDILTLAHTSTEAKGLSESSASS 180
 Db 121 GAGMTTQTITGSDPEBAIFDTLCTDDSSBEAKLTMDILTLAHTSTEAKGLSESSASS 180
 QY 181 DGHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASS 240
 Db 181 DGHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASSDGPHPVITPRAESSASS 240
 QY 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
 Db 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
 QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLGALVTVSRNPLE 360
 Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLGALVTVSRNPLE 360

The invention describes an isolated, secreted and transmembrane polypeptide (PP), termed PRO PP or fibroblast growth factor receptor PP (I). (I) is useful for detecting PRO333, PRO301, PRO187, PRO337, PRO1411, PRO10096, PRO246, PRO6003, fibroblast growth factor receptor (FGFR-1, FGFR-2, FGFR-3, FGFR-4, FGFR-5, PRO2630, PRO2625 or PRO951 polypeptide, and for linking a bioactive molecule to a cell expressing the above polypeptides. The bioactive molecule, a toxin, radiolabel or an antibody, causes cell death. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. Amino polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, to construct hybridisation probes for mapping the gene which encodes the